| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8222536 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 6 Pages |
Abstract
The feasibility of combined vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR) inhibitor therapy, androgen deprivation, and radiation therapy for prostate cancer was established. Using a daily dosing regimen with lead-in, concurrent, and post-XRT therapy, the recommended phase 2 dose of sunitinib is 25 mg daily.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Paul G. MD, PhD, Danny Y. MD, Elisabeth MD, Jordan MD, Raymond PhD, Deborah MD, Thomas A. MD, Paul MD,